Department of Pulmonary Medicine, Kepler University Hospital, Linz, Austria; Faculty of Medicine, Johannes-Kepler-University, Linz, Austria.
Instituto de Investigación, Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Catédra UAM-Linde, Madrid, Spain.
Chest. 2015 Oct;148(4):971-985. doi: 10.1378/chest.14-2535.
COPD ranks within the top three causes of mortality in the global burden of disease, yet it remains largely underdiagnosed. We assessed the underdiagnosis of COPD and its determinants in national and international surveys of general populations.
We analyzed representative samples of adults aged ≥ 40 years randomly selected from well-defined administrative areas worldwide (44 sites from 27 countries). Postbronchodilator FEV1/FVC < lower limit of normal (LLN) was used to define chronic airflow limitation consistent with COPD. Undiagnosed COPD was considered when participants had postbronchodilator FEV1/FVC < LLN but were not given a diagnosis of COPD.
Among 30,874 participants with a mean age of 56 years, 55.8% were women, and 22.9% were current smokers. Population prevalence of (spirometrically defined) COPD ranged from 3.6% in Barranquilla, Colombia, to 19.0% in Cape Town, South Africa. Only 26.4% reported a previous lung function test, and only 5.0% reported a previous diagnosis of COPD, whereas 9.7% had a postbronchodilator FEV1/FVC < LLN. Overall, 81.4% of (spirometrically defined) COPD cases were undiagnosed, with the highest rate in Ile-Ife, Nigeria (98.3%) and the lowest rate in Lexington, Kentucky (50.0%). In multivariate analysis, a greater probability of underdiagnosis of COPD was associated with male sex, younger age, never and current smoking, lower education, no previous spirometry, and less severe airflow limitation.
Even with substantial heterogeneity in COPD prevalence, COPD underdiagnosis is universally high. Because effective management strategies are available for COPD, spirometry can help in the diagnosis of COPD at a stage when treatment will lead to better outcomes and improved quality of life.
慢性阻塞性肺疾病(COPD)在全球疾病负担中位列前三大死因之列,但它在很大程度上仍未被诊断出来。我们评估了在针对普通人群的国家和国际调查中 COPD 的漏诊情况及其决定因素。
我们分析了来自全球明确界定的行政区域中随机选择的年龄≥40 岁的成年人的代表性样本(来自 27 个国家的 44 个地点)。使用支气管扩张剂后 FEV1/FVC<正常下限(LLN)来定义与 COPD 一致的慢性气流受限。当参与者支气管扩张剂后 FEV1/FVC<LLN 但未被诊断为 COPD 时,则认为患有未被诊断的 COPD。
在 30874 名平均年龄为 56 岁的参与者中,55.8%为女性,22.9%为当前吸烟者。(肺量计定义的)COPD 的人群患病率从哥伦比亚巴兰基亚的 3.6%到南非开普敦的 19.0%不等。只有 26.4%的人报告进行过以前的肺功能测试,只有 5.0%的人报告过以前的 COPD 诊断,而 9.7%的人支气管扩张剂后 FEV1/FVC<LLN。总体而言,81.4%的(肺量计定义的)COPD 病例未被诊断,尼日利亚伊费的漏诊率最高(98.3%),肯塔基州列克星敦的漏诊率最低(50.0%)。在多变量分析中,COPD 漏诊的可能性更大与男性、年龄较小、从不吸烟和当前吸烟、受教育程度较低、以前没有进行肺量计检查以及气流受限程度较轻有关。
即使 COPD 的患病率存在很大差异,但 COPD 的漏诊率普遍较高。由于有效的管理策略可用于 COPD,因此肺量计可以帮助在治疗将导致更好的结果和提高生活质量的阶段诊断 COPD。